Vipergen ApS
BioTech/Drugs - Copenhagen, Copenhagen, De
Vipergen ApS Details
Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies.Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies.Vipergen is offering different business models, including simple Fee-For-Service.Recent News- Copenhagen, Denmark, November 6th, 2020 - Commercial release of the first technology for DEL screening inside a living cell - Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process. YoctoReactor® – Technology platform for synthesizing DNA-encoded chemical libraries• 100% match between the DNA-code and the synthesized small molecule is ensured by purification steps after each chemical reaction (unique capability) and use of robust chemistriesBinder Trap Enrichment® – Technology platform for DEL screening in a homogeneous assay• As a homogeneous assay, BTE delivers high fidelity and a low false positive rate by avoiding surface artifacts and the complexity of matrix binding • Instant specificity – multiplexed screening of target and anti-targets (unique capability)Cellular Binder Trap Enrichment® – Technology platform for DEL screening in a living cell• As an in vivo assay, cBTE delivers lower attrition rate (unique capability)• No need for purified active target protein – cBTE accommodates a broader target space (unique capability)
Vipergen ApS Technologies
Load Balancers
Nginx
CMS
WordPress.org
Fonts
Google Font API
Tag Management
Google Tag Manager
Email Delivery
MailJet
Other
Mobile Friendly